CT
About
CytoImmune Therapeutics develops novel, coordinated immunotherapy solutions for patients. Their CoalesceNT platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 10 investors are based in Monrovia, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Monrovia, US
Contact Information
linkedin.com/in/••••••••
Find more investors like CytoImmune
Search Investors